anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The risk of venous thromboembolism (VTE) after hepatopancreatobiliary (HPB) surgery is high. Extended postdischarge prophylaxis in this patient population has been controversial. This study aimed to examine the safety of postdischarge extended VTE prophylaxis in patients at high risk of VTE events after HPB surgery.
METHODS: Adult patients risk stratified as very high risk of VTE who underwent HPB operations between 2014 and 2020 at a quaternary care center were included. Patients were matched 1:2 extended VTE prophylaxis to the control group (patients who did not receive extended prophylaxis). Analyses compared the proportions of adverse bleeding events between groups.
RESULTS: A total of 307 patients were included: 103 in the extended prophylaxis group and 204 in the matched control group. Demographics were similar between groups. More patients in the extended VTE prophylaxis group had a history of VTE (9% vs 3%; P = .045). There was no difference in bleeding events between the extended VTE prophylaxis and the control group (6% vs 2%; P = .091). Of the 6 patients with bleeding events in the VTE prophylaxis group, 5 had gastrointestinal (GI) bleeding, and 1 had hemarthrosis. Of the 4 patients with bleeding events in the control group, 1 had intra-abdominal bleeding, 2 had GI bleeding, and 1 had intra-abdominal and GI bleeding.
CONCLUSION: Patients discharged with extended VTE prophylaxis after HPB surgery did not experience more adverse bleeding events compared with a matched control group. Routine postdischarge extended VTE prophylaxis is safe in patients at high risk of postoperative VTE after HPB surgery.
A split thickness flap will be raised with a micro-blade, keeping a flap thickness \>0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
(1) Background: Hepatocellular carcinoma (HCC) contributes to the significant burden of cancer mortality in the United States (US). Despite highly efficacious antivirals, chronic viral hepatitis (CVH) remains an important cause of HCC. With advancements in therapeutic modalities, along with the aging of the population, we aimed to assess the contribution of CVH in HCC-related mortality in the US between 1999-2020. (2) Methods: We queried all deaths related to CVH and HCC in the multiple-causes-of-death files from the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) database between 1999-2020. Using the direct method of standardization, we adjusted all mortality information for age and compared the age-adjusted mortality rates (AAMRs) across demographic populations and by percentile rankings of social vulnerability. Temporal shifts in mortality were quantified using log-linear regression models. (3) Results: A total of 35,030 deaths were identified between 1999-2020. The overall crude mortality increased from 0.27 in 1999 to 8.32 in 2016, followed by a slight reduction to 7.04 in 2020. The cumulative AAMR during the study period was 4.43 (95% CI, 4.39-4.48). Males (AAMR 7.70) had higher mortality rates compared to females (AAMR 1.44). Mortality was higher among Hispanic populations (AAMR 6.72) compared to non-Hispanic populations (AAMR 4.18). Higher mortality was observed in US counties categorized as the most socially vulnerable (AAMR 5.20) compared to counties that are the least socially vulnerable (AAMR 2.53), with social vulnerability accounting for 2.67 excess deaths per 1,000,000 person-years. (4) Conclusions: Our epidemiological analysis revealed an overall increase in CVH-related HCC mortality between 1999-2008, followed by a stagnation period until 2020. CVH-related HCC mortality disproportionately affected males, Hispanic populations, and Black/African American populations, Western US regions, and socially vulnerable counties. These insights can help aid in the development of strategies to target vulnerable patients, focus on preventive efforts, and allocate resources to decrease HCC-related mortality.
The present invention relates to a composition comprising a material extracted from natural medicine such as Sophora flavescens Aiton, Artemisia princeps var. orientalis HARA, Adhesive Rehmannia, Ulmus davidiana var. japonica Nakai, Pharbitidis Semen, Glycyrrhiza uralensis Fischer, Puerariae Radix, Poria cocas Wolf, Fraxinus rhynchophylla Hance, Agastachis Herba, and the like as an active ingredient. The present invention relates to a manufacturing method of drinking water provided as water supply by depositing the natural medicine in water. Particularly, the manufacturing method can be used for preventing and treating diarrhea, pneumonia, or other diseases of animals such as cattle, pigs, and the like. The type and the concentration of the natural medicine can be variously applicable to uses, a state of fostering, age of the month or age of the year, the species of the provided target, and the like.
An injectable insulin preparation with a protracted effect comprises a suspension of insulin crystals derived wholly or partly from bovine pancreas glands and having the form of sharpedged rhombohedrons limited by plane crystal faces, such that the suspended insulin crystals at pH 6.5-7.5 of the p  suspension medium contain chemically bound within the crystal lattice less than 5 atoms per unit cell of crystallization-promoting metals.  The insulin crystals may be produced by crystallization as described in Specification 733,740 in an aqueous medium containing from 0.2-4.0 mols. per litre of halogen, such as the chlorides, bromides or iodides of alkali metals, alkaline earth metals and ammonia, or by crystallization in presence of trithanolamine hydrochloride, urea or formamide. The crystals are preferably produced with the employment of zinc as crystallization-promoting metal.  Other specified crystallization-promoting metals are nickel, cadmium, cobalt, copper. The suspension medium may be made isotonic with sodium chloride and include a preserving agent, such as methyl-p-hydroxybenzoate, and may be buffered with an acetate, citrate or phosphate buffer.  Insulin crystals in the form of stars, deformed rhombohydrons, rhombohedral twins or lemons may be also suspended in the aqueous medium, as may insulin crystals from swine pancreas.  Crystals having a predetermined size distribution may be employed.  Specification 709,927 also is referred to.
Omega-3 (EPA+DHA) - Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day). Each capsule has 252mg of EPA and 102mg of DHA.
PCT No. PCT/GB91/02286 Sec. 371 Date Jul. 7, 1993 Sec. 102(e) Date Jul. 7, 1993 PCT Filed Dec. 19, 1991 PCT Pub. No. WO/9211260 PCT Pub. Date Jul. 9, 1992.    <IMAGE>  (I)   <IMAGE>  (b)    A compound of formula (I) or, if appropriate, a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent an alkyl group or a moiety of formula (a): -(CH2)m-A, wherein m represents zero or an integer 1, 2 or 3 and A represents a substituted or unsubstituted cyclic hydrocarbon radical; R3 represents hydrogen, NO2 or a halogen atom, an alkoxy group or a group of formula NRsRt wherein Rs and Rt each independently represent hydrogen or alkyl or Rs and Rt together with the nitrogen to which they are attached form a phthalimido group, the phthalimido group being substituted or unsubstituted in the phenylene moiety or R3 represents a moiety of formula (b), wherein R5 represents substituted or unsubstituted alkyl or a substituted or unsubstituted aryl group; and R6 represents hydrogen or a group SO2R7 wherein R7 represents substituted or unsubstituted alkyl, a substituted or unsubstituted aryl group; R4 represents SO2R8, wherein R 8 represents substituted or unsubstituted alkyl or a substituted or unsubstituted aryl group, or, when R3 represents a moiety of the above-defined formula (b), then R4 represents hydrogen or a substituted or unsubstituted alkyl group or a benzyl group substituted or unsubstituted in the phenyl ring a process for preparing such a compound, a composition comprising such a compound and the use of such a compound and composition in medicine.
FIELD: medicine. ^ SUBSTANCE: antibody under the invention is produced from Nicotiana benthamiana leaves by transient transfection of expression vectors. It represents immunoglobulin G and a tetramer consisting of two light and two heavy peptide chains and them larger supramolecular assemblies. The antibody is recovered both in the glycated, and in non-glycated form. The antibody is capable to bind selectively HER2/neu protein, to inhibit cancer cell proliferation. Using the antibody under the invention enables diagnosing HER2-positive breast cancer. ^ EFFECT: invention can be used for preparing drugs and diagnostic agent for breast cancer. ^ 8 dwg, 4 ex
Laparoscopy is currently the gold standard for the vast majority of abdominal surgeries, and especially for colectomy for cancer or benign diseases. There are many data showing the benefits of the laparoscopic approach to colectomy in terms of morbidity, post-operative pain and analgesic consumption, length of hospital stay, cosmetic results, and improved patient satisfaction. In 2002, consensus European guidelines recommended insufflating at the lowest pressure that still provides sufficient exposure. Considering these results, low-pressure laparoscopy is one of the alternatives that have been developed to do away with the complications of the pneumoperitoneum while retaining its advantages.

However, other factors may influence the outcomes of the low-pressure pneumoperitoneum such as the use of humidification and warming gaz, robotic or microsurgical instrumentation, neuromuscular blockade, patient positioning, pre-stretching of the abdominal wall, ventilation-induced changes, and probably individual patient factors like obesity. These parameters could not be separately tested in randomized trial. We should consider all these parameters in a prospective international registry in order to optimize the benefit of low-pressure pneumoperitoneum in post-operative recovery.
BACKGROUND: Coronary heart disease (CHD) is the leading cause of death in both developed and many developing countries. Exercise training is a fundamental component of cardiac rehabilitation programs for patients with CHD. This study aims to investigate the effects of a Tai Chi rehabilitation program, which is provided through a hybrid online and offline mode, on oxidative stress and inflammatory responses in patients with CHD.
METHODS: A total of 34 patients with coronary heart disease were randomly assigned to two groups: an experiment group (n = 14, age 62.07 ± 9.076 years) and a control group (n = 20, age 61.90 ± 9.700 years). The experiment group underwent a 12-week Tai Chi cardiac rehabilitation program (TCCRP), while the control group followed a conventional exercise rehabilitation program (CERP) consisting of 1-h sessions, 3 times per week, for a total of 36 sessions. Participants were studied at baseline and post-intervention. The main assessments include the levels of Malondialdehyde (MDA), Superoxide dismutase (SOD), Tumor necrosis factor (TNF-α) and Interleukin-10 (IL - 10) in blood samples. Pearson correlation analysis was used, and the differences between the two groups were subsequently tested using two-way repeated ANOVA. Statistical significance was defined as a two-sided p-value of <0.05.
RESULTS: The key finding of the study reveals that MDA was significantly reduced by 1.027 nmoL/mL. Additionally, the TCCRP showed significant improvements in SOD and IL-10, with values of 10.110 U/mL and 2.441 pg./mL, respectively. Notably, a significant positive correlation was found between SOD and IL-10 (r = 0.689, p = 0.006), while MDA showed a significant positive correlation with TNF-a (r = 0.542, p = 0.045). In contrast, the ECRP group only showed a significant improvement in SOD.
CONCLUSION: The study conducted a 12-week program on TCCRP, which utilized a hybrid online and offline model for individuals with coronary heart disease. The program showed promising results in alleviating oxidative stress and inflammation, possibly by regulating the balance between oxidative and antioxidative factors, as well as pro-inflammatory and anti-inflammatory factors.
The techniques described herein may provide for an evidence-based, clinical practice guideline-driven, patient communication system. A user (e.g., a patient, a client, etc.) may interact with, or use, a patient communication system for improved healthcare according to one or more aspects. The patient communication system may credibly categorize user inputs into injury patterns (e.g., correlated to healthcare industry established clinical practice guidelines). For instance, an evidence-based, clinical practice guideline-driven, patient communication system may utilize a library of extensive and credible healthcare information (e.g., reviewed by a credible body established by the healthcare industry). Such information may include physical therapy videos, recovery strategies, workplace group or client-group healthcare information, etc. The patient communication system may generate (e.g., based on user input and decision-making trees) patient diagnosis, injury recovery plans, wellness plans, healthcare information reports (e.g., for healthcare clinicians, insurance companies, employers, etc.), and preventative healthcare plans, among other examples.
Patients should be advised of the possible need to reduce levodopa dosage after the initiation of selegiline therapy.

Patients (or their families if the patient is incompetent) should be advised not to exceed the daily recommended dose of 10 mg. The risk of using higher daily doses of selegiline should be explained, and a brief description of the `cheese reaction' provided. Rare hypertensive reactions with selegiline at recommended doses associated with dietary influences have been reported.

Consequently, it may be useful to inform patients (or their families) about the signs and symptoms associated with MAOI induced hypertensive reactions. In particular, patients should be urged to report, immediately, any severe headache or other atypical or unusual symptoms not previously experienced.

There have been reports of patients experiencing intense urges to gamble, increased sexual urges, other intense urges and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone, that are generally used for the treatment of Parkinson’s disease, including selegiline. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped. Prescribers should ask patients about the development of new or increased gambling urges, sexual urges or other urges while being treated with selegiline. Patients should inform their physician if they experience new or increased gambling urges, increased sexual urges or other intense urges while taking selegiline. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking selegiline.
A method provides for changing the refractive power of an eye, and includes the step of selecting a dioptic correction for an eye without compromise for regression of refractive power due to biological response to a change in corneal profile, changing the corneal profile of the eye in order to change the refractive power of the eye to the selected dioptic, (e.g. by laser of surgical procedures) and limiting regression in corneal profile due to the undesired biological response at about the selected diopter by applying to the corneal composition comprising an agent for controlling the biological response. The agent comprised in the composition may be a steroid, a non-steroidal anti-inflammatory agent or a basement membrane component. The change in the refractive power is intended to achieve emmetropia. The method of the present invention allows the correction of refractive/focusing disorders of the eye such as myopia, hyperopia, (a)stigmatism (etc.).
Transradial access has become the most commonly used method for cardiac catheterization. Many medical and technical applications have been proposed to reduce TRA complications. The aim of this study is to examine the effect of hand dominance on radial artery spasm and radial artery occlusionin subjects undergoing CC via TRA. Between April 2020 and August 2022, 1713 subjects who underwent CC via TRA were included in the study. Patient data were obtained in terms of hand dominance of the catheterized side and RAS and RAO during a 1-month follow-up period. RAS was seen in 9.6% of the subjects. The RAS in patients catheterized by the dominant hand was significantly higher than that performed by the non-dominant hand (12 vs 7.8%; P = .004). RAO was seen in 1% of the subjects. RAO was significantly higher in the spasm side than in the no-spasm side (3 vs .8%; P = .009). Hand dominance was determined as an independent predictor of radial artery spasm (P = .006). In our study, RAS and RAO were more common on the dominant hand side than on the non-dominant side. Choosing the non-dominant hand for TRA for CC may reduce the incidence of RAS and RAO.
Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a dry powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolution agent such as citric acid shortly before or at the time of administration. In another embodiment, the insulin is stored as a frozen mixture, ready for use upon thawing.
The present invention relates generally to a method for detecting an aberrant cell in a subject or in a biological sample from said subject and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition. More particularly, the present invention contemplates a method for detecting a cell associated with cancer or having a propensity to develop into a cancer cell in a subject or in a biological sample from said subject by determining the relative increase in the presence of a LIM kinase protein or a related enzyme or a relative increase in LIM kinase activity or a relative increase in the presence of expression products from a gene encoding a LIM kinase or a related protein.  The present invention further provides a method for diagnosing the presence of a cancer or cancerous-like growth or distinguishing between an invasive and non-invasive cancer in a subject or in a biological sample from said subject by screening for up-regulation of a LIM kinase or a related protein in a cell or group of cells or an up-regulation in the presence of expression products of genetic sequences encoding a LIM kinase or a related protein. The present invention provides diagnostic agents useful for detecting LIM kinase or expression products of genetic material encoding LIM kinase. Such diagnostic agents include immunointeractive molecules, such as antibodies, and genetic probes for detecting expression products of LIM kinase genes. The present invention further provides genetically modified animals exhibiting altered levels of LIM kinase. Such animals are useful models for screening for anti-cancer agents.
The study will be a head to head observational study of patients who have undergone gastric bypass surgery. The methods of intraoperative anesthesiology will be Ketamine or Narcotic. Both are FDA approved methods of delivering anesthesia.

The amount of narcotics a patient receives is part of the medical record post-operatively will be followed from post-anesthesia care unit (PACU) through to discharge. The amount of narcotics needed to control the patient's pain (converted to morphine equivalent units) and pain scores (a hospital standard measure) will be collected for 48 hours for the study, or until discharge, whichever occurs sooner. The conversion to a morphine equivalent unit allows investigators to compare different narcotics the patient may receive in a more standardized way. The results will be analyzed and compared between the two groups.
Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose \>0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
Studies have shown that the voiding cystourethrogram (VCUG) can be distressful and painful for children as the child is catheterized during the procedure. Currently no sedation or analgesia is recommended for the procedure. The practice of pediatrics is constantly seeking measures to decrease pain and distress for children. The opioid fentanyl was originally synthesized in the 1950's and 60's as an alternative to morphine and meperidine. The safety and efficacy of intranasal (IN) fentanyl has been previously demonstrated in the setting of a pediatric emergency department.

We are proposing the use of IN fentanyl for analgesia prior to the catheterization for a voiding cystourethrogram (VCUG). If we prove that IN fentanyl is effective in reducing the pain while ensuring patient safety, it could become the analgesic of choice for this procedure.